Comera Life Sciences (CMRA) Competitors $0.0002 0.00 (0.00%) As of 07/3/2025 Add Compare Share Share Competitors Stock AnalysisChartCompetitorsInsider TradesSEC FilingsShort InterestTrendsBuy This Stock CMRA vs. NAVB, SCPS, VAXX, EVLO, GNCAQ, GNCA, ARDS, STAB, EFTR, and HSTOShould you be buying Comera Life Sciences stock or one of its competitors? The main competitors of Comera Life Sciences include Navidea Biopharmaceuticals (NAVB), Scopus BioPharma (SCPS), Vaxxinity (VAXX), Evelo Biosciences (EVLO), Genocea Biosciences (GNCAQ), Genocea Biosciences (GNCA), Aridis Pharmaceuticals (ARDS), Statera Biopharma (STAB), eFFECTOR Therapeutics (EFTR), and Histogen (HSTO). These companies are all part of the "pharmaceutical products" industry. Comera Life Sciences vs. Its Competitors Navidea Biopharmaceuticals Scopus BioPharma Vaxxinity Evelo Biosciences Genocea Biosciences Genocea Biosciences Aridis Pharmaceuticals Statera Biopharma eFFECTOR Therapeutics Histogen Comera Life Sciences (NASDAQ:CMRA) and Navidea Biopharmaceuticals (NYSE:NAVB) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their valuation, institutional ownership, analyst recommendations, dividends, media sentiment, profitability, risk and earnings. Which has more volatility and risk, CMRA or NAVB? Comera Life Sciences has a beta of 1.27, meaning that its share price is 27% more volatile than the S&P 500. Comparatively, Navidea Biopharmaceuticals has a beta of 1.75, meaning that its share price is 75% more volatile than the S&P 500. Does the media prefer CMRA or NAVB? In the previous week, Comera Life Sciences' average media sentiment score of 0.00 equaled Navidea Biopharmaceuticals'average media sentiment score. Company Overall Sentiment Comera Life Sciences Neutral Navidea Biopharmaceuticals Neutral Do insiders and institutionals have more ownership in CMRA or NAVB? 0.0% of Navidea Biopharmaceuticals shares are held by institutional investors. 8.9% of Comera Life Sciences shares are held by insiders. Comparatively, 43.7% of Navidea Biopharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth. Which has preferable valuation & earnings, CMRA or NAVB? Navidea Biopharmaceuticals has lower revenue, but higher earnings than Comera Life Sciences. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioComera Life Sciences$1.00M0.01-$18MN/AN/ANavidea Biopharmaceuticals$8.13K2.46-$15.18MN/AN/A Is CMRA or NAVB more profitable? Company Net Margins Return on Equity Return on Assets Comera Life SciencesN/A N/A N/A Navidea Biopharmaceuticals N/A N/A N/A SummaryNavidea Biopharmaceuticals beats Comera Life Sciences on 5 of the 6 factors compared between the two stocks. Get Comera Life Sciences News Delivered to You Automatically Sign up to receive the latest news and ratings for CMRA and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding CMRA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart CMRA vs. The Competition Export to ExcelMetricComera Life SciencesPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$6K$790.76M$5.53B$9.04BDividend YieldN/A4.84%5.24%4.02%P/E RatioN/A1.3727.5820.25Price / Sales0.01230.41417.23118.60Price / CashN/A23.4436.8958.07Price / BookN/A6.298.035.67Net Income-$18M-$27.99M$3.18B$249.21M7 Day PerformanceN/A1.94%2.91%3.28%1 Month PerformanceN/A10.03%3.72%5.56%1 Year PerformanceN/A10.92%36.04%21.13% Comera Life Sciences Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)CMRAComera Life SciencesN/A$0.00flatN/A-99.2%$6K$1.00M0.002NAVBNavidea BiopharmaceuticalsN/A$0.00-80.0%N/A-80.0%$20K$8.13K0.0010Gap DownHigh Trading VolumeSCPSScopus BioPharmaN/A$0.00flatN/AN/A$13KN/A0.009VAXXVaxxinityN/A$0.00flatN/A-90.3%$13KN/A0.0090Gap UpEVLOEvelo BiosciencesN/A$0.00flatN/AN/A$9KN/A0.00120Upcoming EarningsGNCAQGenocea BiosciencesN/AN/AN/AN/A$6KN/A0.0070GNCAGenocea BiosciencesN/AN/AN/AN/A$6K$1.91M0.0070ARDSAridis PharmaceuticalsN/A$0.00flatN/AN/A$5K$3.09M0.0030STABStatera BiopharmaN/A$0.00flatN/AN/A$5KN/A0.0020EFTReFFECTOR TherapeuticsN/A$0.00flatN/A-99.8%$1K$3.55M0.0010HSTOHistogenN/A$0.00-98.0%N/A-99.9%$1K$19K0.0020Gap Down Related Companies and Tools Related Companies NAVB Competitors SCPS Competitors VAXX Competitors EVLO Competitors GNCAQ Competitors GNCA Competitors ARDS Competitors STAB Competitors EFTR Competitors HSTO Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:CMRA) was last updated on 7/5/2025 by MarketBeat.com Staff From Our PartnersA new rule goes live in July — and the banks are quietly cashing inA little-known regulation quietly goes into effect this July. And it's already being exploited by Wall Stre...American Alternative | SponsoredTrump’s Exec Order #14154 could be a “Millionaire-Maker”Former Presidential Advisor, Jim Rickards, says Trump could “rewire our economy and hand millions of Americans...Paradigm Press | SponsoredTrump’s New Order Could Boost Social Security Benefits by 400%If you collect—or plan to collect—Social Security, you need to see this. A new initiative tied to President...InvestorPlace | SponsoredPost-Halving = Profit Season (Here’s How to Win It)It happens like clockwork. Every four years, the crypto market enters a new phase — and for those who know how...Crypto Swap Profits | SponsoredElon’s NEXT Big IPO?Cancel your internet TODAY!? Take your latest internet bill and light it on fire… then count the seconds it...Banyan Hill Publishing | SponsoredWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | SponsoredTrump wipes out trillions overnight…Is there anybody more powerful than Donald Trump right now? In a single tariff announcement, he wiped out n...Porter & Company | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Comera Life Sciences Holdings, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Comera Life Sciences With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free CMRA Stock Alerts